Skip to main content
Home

Syndicate contenthyperthyroidism

Shire presents study findings on its ADHD treatments at psychiatric meeting Oct 29-30

HONOLULU -- October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Defi

Vyvanse CII significantly improved ADHD symptoms for children 13 hours after administration

PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi

VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD

Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Accurate assessment of heart disease leads to earlier, more aggressive therapy

Reston, Va.--In a study comparing the ability of various medical techniques to accurately determine the extent of heart disease and stratify patients according to disease severity, researchers found that myocardial perfusion testing with gated single photon emission computed tomography (gated SPECT) was a more accurate predictor of prognosis in chronic ischemic heart disease (IHD)--a painful co



About us

Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.




Premium Drupal Themes by Adaptivethemes